Literature DB >> 11126261

Do we need new indications for ECMO in neonates pretreated with high-frequency ventilation and/or inhaled nitric oxide?

H Kössel1, K Bauer, G Kewitz, S Karaca, H Versmold.   

Abstract

OBJECTIVE: High-frequency ventilation (HFV) and/or inhaled nitric oxide (iNO) has reduced ECMO in neonates. But, frequently, improvement with HFV/iNO is temporary and only prolongs lung injury without preventing ECMO. We tried to identify a threshold oxygenation index (OI) that predicts temporary or persistent improvement with HFV/iNO in neonatal ECMO candidates as early as possible.
DESIGN: Cohort study of all neonates with OI > 40 during intermittent positive pressure ventilation between 1992 and 1997. The first treatment was HFV; at an OI > 40 during HFV, iNO was added; at an OI > 40 during HFV+iNO, ECMO was initiated. Temporary improvement was defined as secondary need for ECMO or fatal chronic lung disease without ECMO.
SETTING: University hospital level III neonatal intensive care unit. MAIN
RESULTS: Ten of the 34 neonates studied rapidly required ECMO despite HFV/iNO. Eleven neonates temporarily improved for 1-10 days before the OI was again > 40. Nine received ECMO, two were denied ECMO after mechanical ventilation > 14 days and died of chronic lung disease. Thirteen neonates persistently improved with HFV/iNO without ECMO. The OI before, at 24 h or 48 h of HFV/iNO did not predict temporary or persistent improvement. However, after 72 h of HFV/iNO, neonates with persistent improvement had lower OIs than those with temporary improvement [median OI 16 (4-24) vs 31 (20-40); P = 0.0004]. In all neonates with an OI > or = 25 after 72 h, HFV/iNO eventually failed (positive predictive value 100%, sensitivity 91 %, specificity 100%, positive likelihood ratio 91).
CONCLUSION: For neonates pretreated with HFV/iNO, an OI > 40 is an inadequate ECMO indication. Based on our data we hypothesize that an OI > or = 25 after 72 h of HFV/ iNO is a better ECMO indication that avoids prolonged barotrauma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126261     DOI: 10.1007/s001340000603

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience.

Authors:  K Khambekar; S Nichani; D K Luyt; G Peek; R K Firmin; D J Field; H C Pandya
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-09-13       Impact factor: 5.747

Review 2.  Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

Authors:  Enrique M Ostrea; Esterlita T Villanueva-Uy; Girija Natarajan; Herbert G Uy
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center.

Authors:  T Schaible; D Hermle; F Loersch; S Demirakca; K Reinshagen; V Varnholt
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

4.  Adapted ECMO criteria for newborns with persistent pulmonary hypertension after inhaled nitric oxide and/or high-frequency oscillatory ventilation.

Authors:  Saskia van Berkel; Mathijs Binkhorst; Arno F J van Heijst; Marc H W A Wijnen; Kian D Liem
Journal:  Intensive Care Med       Date:  2013-04-12       Impact factor: 17.440

5.  Defining the late implementation of extracorporeal membrane oxygenation (ECMO) by identifying increased mortality risk using specific physiologic cut-points in neonatal and pediatric respiratory patients.

Authors:  Gary Grist; Carrie Whittaker; Kellie Merrigan; Jason Fenton; Eugenia Pallotto; Gary Lofland
Journal:  J Extra Corpor Technol       Date:  2009-12

6.  Patient selection for neonatal extracorporeal membrane oxygenation: beyond severity of illness.

Authors:  R L Chapman; S M Peterec; M J Bizzarro; M R Mercurio
Journal:  J Perinatol       Date:  2009-05-21       Impact factor: 2.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.